Table 2.
Comparison of dose-adjusted mean trough concentrations of lenvatinib between genotypes of ABC transporters and CYP3A4/5.
| Genotype | n | Dose-adjusted C0 (ng/mL/mg) | P value | |
|---|---|---|---|---|
| Median | Minimum - Maximum | |||
| ABCB1 1236C > T | ||||
| C/C | 8 | 4.37 | (1.67–10.4) | 0.303a |
| C/T | 22 | 5.87 | (1.40–12.6) | |
| T/T | 10 | 5.85 | (3.24–11.0) | |
| ABCB1 2677G > T/A | ||||
| G/G | 9 | 5.08 | (3.09–12.6) | 0.755a |
| G/T + G/A | 19 | 5.67 | (1.40–11.0) | |
| T/T + T/A + A/A | 12 | 5.62 | (2.06–11.0) | |
| ABCB1 3435C > T | ||||
| C/C | 14 | 4.90 | (1.40–12.6) | 0.724a |
| C/T | 21 | 5.52 | (2.06–11.0) | |
| T/T | 5 | 6.02 | (4.24–7.46) | |
| ABCG2 421C > A | ||||
| C/C | 20 | 4.73 | (1.40–12.6) | 0.063b |
| C/A + A/A | 20 | 6.34 | (1.67–10.4) | |
| ABCC2 −24C > T | ||||
| C/C | 24 | 5.03 | (1.40–12.6) | 0.036b |
| C/T + T/T | 16 | 6.57 | (4.06–11.0) | |
| CYP3A4 20230G > A(*1G) | ||||
| *1/*1 | 24 | 6.34 | (1.40–12.6) | 0.018b |
| *1/*1 G + *1 G/*1G | 16 | 4.77 | (1.67–7.52) | |
| CYP3A5 6986 A > G(*3) | ||||
| *1/*1 + *1/*3 | 14 | 4.77 | (1.67–10.4) | 0.063b |
| *3/*3 | 26 | 6.22 | (1.40–12.6) | |
| Sex | ||||
| Female | 27 | 5.67 | (1.67–12.6) | 0.252b |
| Male | 13 | 5.08 | (1.40–10.4) | |
| Correlation coefficient (r) | ||||
| Age (years) | 0.061 | 0.817 | ||
| Body weight (kg) | −0.220 | 0.414 | ||
| Laboratory test values at lenvatinib initiation | ||||
| Aspartate transaminase | 0.273 | 0.098 | ||
| Alanine transaminase | 0.151 | 0.388 | ||
| Serum albumin | 0.189 | 0.249 | ||
| Total bilirubin | 0.336 | 0.037 | ||
| Serum creatinine | −0.151 | 0.357 | ||
aKruskal Wallis, bMann-Whitney.
The dose-adjusted C0 of lenvatinib for each patient was calculated using the average of several C0 values at the steady-state.